Optimizing treatment outcomes with phosphodiesterase type 5 inhibitors for erectile dysfunction: Opening windows to enhanced sexual function and overall health
Identifieur interne : 001384 ( Istex/Corpus ); précédent : 001383; suivant : 001385Optimizing treatment outcomes with phosphodiesterase type 5 inhibitors for erectile dysfunction: Opening windows to enhanced sexual function and overall health
Auteurs : Richard Sadovsky ; Gerald B. Brock ; Mikel Gray ; Penny Kaye Jensen ; Stephen W. Gutkin ; Sebastian SorsaburuSource :
- Journal of the American Academy of Nurse Practitioners [ 1041-2972 ] ; 2011-06.
English descriptors
- KwdEn :
Abstract
Purpose: Phosphodiesterase type 5 (PDE5) inhibitors have proved to be efficacious, safe, and well tolerated, in clinical trials and practice, for men with erectile dysfunction (ED). However, many patients are not satisfied with treatment and discontinue it prematurely. This review discusses evidence‐based strategies that nurse practitioners (NPs) can use to improve diagnosis of ED, optimize patient outcomes, and identify opportunities to detect other potentially serious comorbid conditions.
Url:
DOI: 10.1111/j.1745-7599.2010.00590.x
Links to Exploration step
ISTEX:56297BF96D594B7B3EA523336A55CF21814D53FALe document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Optimizing treatment outcomes with phosphodiesterase type 5 inhibitors for erectile dysfunction: Opening windows to enhanced sexual function and overall health</title><author><name sortKey="Sadovsky, Richard" sort="Sadovsky, Richard" uniqKey="Sadovsky R" first="Richard" last="Sadovsky">Richard Sadovsky</name><affiliation><mods:affiliation>State University of New York Health Science Center at Brooklyn (SUNY Downstate Medical Center) and Kings County Hospital Center, Brooklyn, New York</mods:affiliation></affiliation></author><author><name sortKey="Brock, Gerald B" sort="Brock, Gerald B" uniqKey="Brock G" first="Gerald B." last="Brock">Gerald B. Brock</name><affiliation><mods:affiliation>Division of Urology, Faculty of Medicine and Dentistry, University of Western Ontario, London, Ontario, Canada</mods:affiliation></affiliation></author><author><name sortKey="Gray, Mikel" sort="Gray, Mikel" uniqKey="Gray M" first="Mikel" last="Gray">Mikel Gray</name><affiliation><mods:affiliation>Department of Urology, School of Nursing, University of Nursing, Charlottesville, Virginia</mods:affiliation></affiliation></author><author><name sortKey="Jensen, Penny Kaye" sort="Jensen, Penny Kaye" uniqKey="Jensen P" first="Penny Kaye" last="Jensen">Penny Kaye Jensen</name><affiliation><mods:affiliation>Salt Lake City Veterans Affairs Medical Center & University of Utah College of Nursing, Salt Lake City, Utah</mods:affiliation></affiliation></author><author><name sortKey="Gutkin, Stephen W" sort="Gutkin, Stephen W" uniqKey="Gutkin S" first="Stephen W." last="Gutkin">Stephen W. Gutkin</name><affiliation><mods:affiliation>Rete Biomedical Communications Corp., Wyckoff, New Jersey</mods:affiliation></affiliation></author><author><name sortKey="Sorsaburu, Sebastian" sort="Sorsaburu, Sebastian" uniqKey="Sorsaburu S" first="Sebastian" last="Sorsaburu">Sebastian Sorsaburu</name><affiliation><mods:affiliation>Eli Lilly and Company, Indianapolis, Indiana</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:56297BF96D594B7B3EA523336A55CF21814D53FA</idno><date when="2011" year="2011">2011</date><idno type="doi">10.1111/j.1745-7599.2010.00590.x</idno><idno type="url">https://api.istex.fr/document/56297BF96D594B7B3EA523336A55CF21814D53FA/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">001384</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">001384</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Optimizing treatment outcomes with phosphodiesterase type 5 inhibitors for erectile dysfunction: Opening windows to enhanced sexual function and overall health</title><author><name sortKey="Sadovsky, Richard" sort="Sadovsky, Richard" uniqKey="Sadovsky R" first="Richard" last="Sadovsky">Richard Sadovsky</name><affiliation><mods:affiliation>State University of New York Health Science Center at Brooklyn (SUNY Downstate Medical Center) and Kings County Hospital Center, Brooklyn, New York</mods:affiliation></affiliation></author><author><name sortKey="Brock, Gerald B" sort="Brock, Gerald B" uniqKey="Brock G" first="Gerald B." last="Brock">Gerald B. Brock</name><affiliation><mods:affiliation>Division of Urology, Faculty of Medicine and Dentistry, University of Western Ontario, London, Ontario, Canada</mods:affiliation></affiliation></author><author><name sortKey="Gray, Mikel" sort="Gray, Mikel" uniqKey="Gray M" first="Mikel" last="Gray">Mikel Gray</name><affiliation><mods:affiliation>Department of Urology, School of Nursing, University of Nursing, Charlottesville, Virginia</mods:affiliation></affiliation></author><author><name sortKey="Jensen, Penny Kaye" sort="Jensen, Penny Kaye" uniqKey="Jensen P" first="Penny Kaye" last="Jensen">Penny Kaye Jensen</name><affiliation><mods:affiliation>Salt Lake City Veterans Affairs Medical Center & University of Utah College of Nursing, Salt Lake City, Utah</mods:affiliation></affiliation></author><author><name sortKey="Gutkin, Stephen W" sort="Gutkin, Stephen W" uniqKey="Gutkin S" first="Stephen W." last="Gutkin">Stephen W. Gutkin</name><affiliation><mods:affiliation>Rete Biomedical Communications Corp., Wyckoff, New Jersey</mods:affiliation></affiliation></author><author><name sortKey="Sorsaburu, Sebastian" sort="Sorsaburu, Sebastian" uniqKey="Sorsaburu S" first="Sebastian" last="Sorsaburu">Sebastian Sorsaburu</name><affiliation><mods:affiliation>Eli Lilly and Company, Indianapolis, Indiana</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">Journal of the American Academy of Nurse Practitioners</title><idno type="ISSN">1041-2972</idno><idno type="eISSN">1745-7599</idno><imprint><publisher>Blackwell Publishing Inc</publisher><pubPlace>Malden, USA</pubPlace><date type="published" when="2011-06">2011-06</date><biblScope unit="volume">23</biblScope><biblScope unit="issue">6</biblScope><biblScope unit="page" from="320">320</biblScope><biblScope unit="page" to="330">330</biblScope></imprint><idno type="ISSN">1041-2972</idno></series><idno type="istex">56297BF96D594B7B3EA523336A55CF21814D53FA</idno><idno type="DOI">10.1111/j.1745-7599.2010.00590.x</idno><idno type="ArticleID">JAAN590</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">1041-2972</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Assessment</term><term>drug therapy</term><term>erectile dysfunction</term><term>phosphodiesterases</term><term>risk factors</term><term>sexual activity</term><term>treatment outcomes</term><term>vasoactive agents</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract">Purpose: Phosphodiesterase type 5 (PDE5) inhibitors have proved to be efficacious, safe, and well tolerated, in clinical trials and practice, for men with erectile dysfunction (ED). However, many patients are not satisfied with treatment and discontinue it prematurely. This review discusses evidence‐based strategies that nurse practitioners (NPs) can use to improve diagnosis of ED, optimize patient outcomes, and identify opportunities to detect other potentially serious comorbid conditions.</div></front></TEI><istex><corpusName>wiley</corpusName><author><json:item><name>Richard Sadovsky MD, MPH, FAAFP (Associate Professor of Family Medicine)</name><affiliations><json:string>State University of New York Health Science Center at Brooklyn (SUNY Downstate Medical Center) and Kings County Hospital Center, Brooklyn, New York</json:string></affiliations></json:item><json:item><name>Gerald B. Brock MD, FRCSC (Professor of Urology)</name><affiliations><json:string>Division of Urology, Faculty of Medicine and Dentistry, University of Western Ontario, London, Ontario, Canada</json:string></affiliations></json:item><json:item><name>Mikel Gray PhD, FAANP (Professor of Acute & Specialty Care)</name><affiliations><json:string>Department of Urology, School of Nursing, University of Nursing, Charlottesville, Virginia</json:string></affiliations></json:item><json:item><name>Penny Kaye Jensen DNP, FNP‐C, FAANP (Assistant Professor of Acute & Chronic Care, Clinical Director of Non‐Surgical Erectile Dysfunction Clinic)</name><affiliations><json:string>Salt Lake City Veterans Affairs Medical Center & University of Utah College of Nursing, Salt Lake City, Utah</json:string></affiliations></json:item><json:item><name>Stephen W. Gutkin BA</name><affiliations><json:string>Rete Biomedical Communications Corp., Wyckoff, New Jersey</json:string></affiliations></json:item><json:item><name>Sebastian Sorsaburu MD (Senior Medical Advisor, Global Drug Development)</name><affiliations><json:string>Eli Lilly and Company, Indianapolis, Indiana</json:string></affiliations></json:item></author><subject><json:item><lang><json:string>eng</json:string></lang><value>Assessment</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>drug therapy</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>erectile dysfunction</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>phosphodiesterases</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>risk factors</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>sexual activity</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>treatment outcomes</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>vasoactive agents</value></json:item></subject><articleId><json:string>JAAN590</json:string></articleId><language><json:string>eng</json:string></language><originalGenre><json:string>reviewArticle</json:string></originalGenre><qualityIndicators><score>6.304</score><pdfVersion>1.4</pdfVersion><pdfPageSize>585 x 783 pts</pdfPageSize><refBibsNative>true</refBibsNative><abstractCharCount>495</abstractCharCount><pdfWordCount>7715</pdfWordCount><pdfCharCount>51329</pdfCharCount><pdfPageCount>11</pdfPageCount><abstractWordCount>67</abstractWordCount></qualityIndicators><title>Optimizing treatment outcomes with phosphodiesterase type 5 inhibitors for erectile dysfunction: Opening windows to enhanced sexual function and overall health</title><genre><json:string>review-article</json:string></genre><host><volume>23</volume><publisherId><json:string>JAAN</json:string></publisherId><pages><total>11</total><last>330</last><first>320</first></pages><issn><json:string>1041-2972</json:string></issn><issue>6</issue><subject><json:item><value>REVIEW</value></json:item></subject><genre><json:string>journal</json:string></genre><language><json:string>unknown</json:string></language><eissn><json:string>1745-7599</json:string></eissn><title>Journal of the American Academy of Nurse Practitioners</title><doi><json:string>10.1111/(ISSN)1745-7599</json:string></doi></host><categories><wos><json:string>social science</json:string><json:string>nursing</json:string><json:string>science</json:string><json:string>health care sciences & services</json:string></wos><scienceMetrix><json:string>health sciences</json:string><json:string>public health & health services</json:string><json:string>nursing</json:string></scienceMetrix></categories><publicationDate>2011</publicationDate><copyrightDate>2011</copyrightDate><doi><json:string>10.1111/j.1745-7599.2010.00590.x</json:string></doi><id>56297BF96D594B7B3EA523336A55CF21814D53FA</id><score>1</score><fulltext><json:item><extension>pdf</extension><original>true</original><mimetype>application/pdf</mimetype><uri>https://api.istex.fr/document/56297BF96D594B7B3EA523336A55CF21814D53FA/fulltext/pdf</uri></json:item><json:item><extension>zip</extension><original>false</original><mimetype>application/zip</mimetype><uri>https://api.istex.fr/document/56297BF96D594B7B3EA523336A55CF21814D53FA/fulltext/zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/document/56297BF96D594B7B3EA523336A55CF21814D53FA/fulltext/tei"><teiHeader><fileDesc><titleStmt><title level="a" type="main" xml:lang="en">Optimizing treatment outcomes with phosphodiesterase type 5 inhibitors for erectile dysfunction: Opening windows to enhanced sexual function and overall health</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>Blackwell Publishing Inc</publisher><pubPlace>Malden, USA</pubPlace><availability><p>©2011 The Author(s) Journal compilation ©2011 American Academy of Nurse Practitioners</p></availability><date>2011</date></publicationStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a" type="main" xml:lang="en">Optimizing treatment outcomes with phosphodiesterase type 5 inhibitors for erectile dysfunction: Opening windows to enhanced sexual function and overall health</title><author xml:id="author-1"><persName><forename type="first">Richard</forename><surname>Sadovsky</surname></persName><roleName type="degree">MD, MPH, FAAFP (Associate Professor of Family Medicine)</roleName><affiliation>State University of New York Health Science Center at Brooklyn (SUNY Downstate Medical Center) and Kings County Hospital Center, Brooklyn, New York</affiliation></author><author xml:id="author-2"><persName><forename type="first">Gerald B.</forename><surname>Brock</surname></persName><roleName type="degree">MD, FRCSC (Professor of Urology)</roleName><affiliation>Division of Urology, Faculty of Medicine and Dentistry, University of Western Ontario, London, Ontario, Canada</affiliation></author><author xml:id="author-3"><persName><forename type="first">Mikel</forename><surname>Gray</surname></persName><roleName type="degree">PhD, FAANP (Professor of Acute & Specialty Care)</roleName><affiliation>Department of Urology, School of Nursing, University of Nursing, Charlottesville, Virginia</affiliation></author><author xml:id="author-4"><persName><forename type="first">Penny Kaye</forename><surname>Jensen</surname></persName><roleName type="degree">DNP, FNP‐C, FAANP (Assistant Professor of Acute & Chronic Care, Clinical Director of Non‐Surgical Erectile Dysfunction Clinic)</roleName><affiliation>Salt Lake City Veterans Affairs Medical Center & University of Utah College of Nursing, Salt Lake City, Utah</affiliation></author><author xml:id="author-5"><persName><forename type="first">Stephen W.</forename><surname>Gutkin</surname></persName><roleName type="degree">BA</roleName><affiliation>Rete Biomedical Communications Corp., Wyckoff, New Jersey</affiliation></author><author xml:id="author-6"><persName><forename type="first">Sebastian</forename><surname>Sorsaburu</surname></persName><roleName type="degree">MD (Senior Medical Advisor, Global Drug Development)</roleName><affiliation>Eli Lilly and Company, Indianapolis, Indiana</affiliation></author></analytic><monogr><title level="j">Journal of the American Academy of Nurse Practitioners</title><idno type="pISSN">1041-2972</idno><idno type="eISSN">1745-7599</idno><idno type="DOI">10.1111/(ISSN)1745-7599</idno><imprint><publisher>Blackwell Publishing Inc</publisher><pubPlace>Malden, USA</pubPlace><date type="published" when="2011-06"></date><biblScope unit="volume">23</biblScope><biblScope unit="issue">6</biblScope><biblScope unit="page" from="320">320</biblScope><biblScope unit="page" to="330">330</biblScope></imprint></monogr><idno type="istex">56297BF96D594B7B3EA523336A55CF21814D53FA</idno><idno type="DOI">10.1111/j.1745-7599.2010.00590.x</idno><idno type="ArticleID">JAAN590</idno></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>2011</date></creation><langUsage><language ident="en">en</language></langUsage><abstract><p>Purpose: Phosphodiesterase type 5 (PDE5) inhibitors have proved to be efficacious, safe, and well tolerated, in clinical trials and practice, for men with erectile dysfunction (ED). However, many patients are not satisfied with treatment and discontinue it prematurely. This review discusses evidence‐based strategies that nurse practitioners (NPs) can use to improve diagnosis of ED, optimize patient outcomes, and identify opportunities to detect other potentially serious comorbid conditions.</p></abstract><abstract><p>Data sources: This article was based on a previously published review, which involved a PubMed–MEDLINE search of the clinical literature from January 1, 1998 (year of sildenafil's approval in many markets), through August 30, 2008 (date of search).</p></abstract><abstract><p>Conclusions: Strategies to optimize responses to PDE5 therapy are summarized by the mnemonic “EPOCH”: Evaluating and educating to ensure realistic expectations of therapy; Prescribing a treatment individualized to the couple's needs and preferences; Optimizing drug dose/regimen and revisiting key educational messages at follow‐up visits; Controlling comorbidities via lifestyle counseling, medications, and/or referrals; and Helping patients and their partners to seek other forms of therapy if they have decided not to use a PDE5 inhibitor.</p></abstract><abstract><p>Implications for practice: The “EPOCH” mnemonic may remind NPs of steps to optimize treatment outcomes with PDE5 inhibitors.</p></abstract><textClass xml:lang="en"><keywords scheme="keyword"><list><head>keywords</head><item><term>Assessment</term></item><item><term>drug therapy</term></item><item><term>erectile dysfunction</term></item><item><term>phosphodiesterases</term></item><item><term>risk factors</term></item><item><term>sexual activity</term></item><item><term>treatment outcomes</term></item><item><term>vasoactive agents</term></item></list></keywords></textClass><textClass><keywords scheme="Journal Subject"><list><head>article-category</head><item><term>REVIEW</term></item></list></keywords></textClass></profileDesc><revisionDesc><change when="2011-06">Published</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><extension>txt</extension><original>false</original><mimetype>text/plain</mimetype><uri>https://api.istex.fr/document/56297BF96D594B7B3EA523336A55CF21814D53FA/fulltext/txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Wiley, elements deleted: body"><istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="yes"</istex:xmlDeclaration><istex:document><component version="2.0" type="serialArticle" xml:lang="en"><header><publicationMeta level="product"><publisherInfo><publisherName>Blackwell Publishing Inc</publisherName><publisherLoc>Malden, USA</publisherLoc></publisherInfo><doi origin="wiley" registered="yes">10.1111/(ISSN)1745-7599</doi><issn type="print">1041-2972</issn><issn type="electronic">1745-7599</issn><idGroup><id type="product" value="JAAN"></id><id type="publisherDivision" value="ST"></id></idGroup><titleGroup><title type="main" sort="JOURNAL OF AMERICAN ACADEMY NURSE PRACTITIONERS">Journal of the American Academy of Nurse Practitioners</title></titleGroup></publicationMeta><publicationMeta level="part" position="06106"><doi origin="wiley">10.1111/jaan.2011.23.issue-6</doi><numberingGroup><numbering type="journalVolume" number="23">23</numbering><numbering type="journalIssue" number="6">6</numbering></numberingGroup><coverDate startDate="2011-06">June 2011</coverDate></publicationMeta><publicationMeta level="unit" type="reviewArticle" position="8" status="forIssue"><doi origin="wiley">10.1111/j.1745-7599.2010.00590.x</doi><idGroup><id type="unit" value="JAAN590"></id></idGroup><countGroup><count type="pageTotal" number="11"></count></countGroup><titleGroup><title type="tocHeading1">REVIEW</title><title type="articleCategory">REVIEW</title></titleGroup><copyright>©2011 The Author(s) Journal compilation ©2011 American Academy of Nurse Practitioners</copyright><eventGroup><event type="xmlConverted" agent="Converter:BPG_TO_WML3G version:2.5.2 mode:FullText" date="2011-07-06"></event><event type="publishedOnlineEarlyUnpaginated" date="2011-01-27"></event><event type="publishedOnlineFinalForm" date="2011-06-07"></event><event type="firstOnline" date="2011-01-27"></event><event type="xmlConverted" agent="Converter:WILEY_ML3G_TO_WILEY_ML3GV2 version:3.8.8" date="2014-01-28"></event><event type="xmlConverted" agent="Converter:WML3G_To_WML3G version:4.1.7 mode:FullText,remove_FC" date="2014-10-30"></event></eventGroup><numberingGroup><numbering type="pageFirst" number="320">320</numbering><numbering type="pageLast" number="330">330</numbering></numberingGroup><correspondenceTo><b>Correspondence</b>
Richard Sadovsky, MD, MPH, FAAFP, 450 Clarkson Ave., Brooklyn, NY 11203.
Tel: 718‐270‐4096;
Fax: 718‐270‐2125; E‐mail: <email>rsadovsk@aol.com</email></correspondenceTo><linkGroup><link type="toTypesetVersion" href="file:JAAN.JAAN590.pdf"></link></linkGroup></publicationMeta><contentMeta><unparsedEditorialHistory>Received: January 2010;, accepted: April 2010</unparsedEditorialHistory><countGroup><count type="figureTotal" number="2"></count><count type="tableTotal" number="4"></count><count type="formulaTotal" number="0"></count><count type="referenceTotal" number="90"></count><count type="linksCrossRef" number="130"></count></countGroup><titleGroup><title type="main">Optimizing treatment outcomes with phosphodiesterase type 5 inhibitors for erectile dysfunction: Opening windows to enhanced sexual function and overall health</title><title type="shortAuthors">R. Sadovsky et al.</title><title type="short">Optimizing ED outcomes with PDE5 inhibitors</title></titleGroup><creators><creator creatorRole="author" xml:id="cr1" affiliationRef="#a1"><personName><givenNames>Richard</givenNames><familyName>Sadovsky</familyName><degrees>MD, MPH, FAAFP (Associate Professor of Family Medicine)</degrees></personName></creator><creator creatorRole="author" xml:id="cr2" affiliationRef="#a2"><personName><givenNames>Gerald B.</givenNames><familyName>Brock</familyName><degrees>MD, FRCSC (Professor of Urology)</degrees></personName></creator><creator creatorRole="author" xml:id="cr3" affiliationRef="#a3"><personName><givenNames>Mikel</givenNames><familyName>Gray</familyName><degrees>PhD, FAANP (Professor of Acute & Specialty Care)</degrees></personName></creator><creator creatorRole="author" xml:id="cr4" affiliationRef="#a4"><personName><givenNames>Penny Kaye</givenNames><familyName>Jensen</familyName><degrees>DNP, FNP‐C, FAANP (Assistant Professor of Acute & Chronic Care, Clinical Director of Non‐Surgical Erectile Dysfunction Clinic)</degrees></personName></creator><creator creatorRole="author" xml:id="cr5" affiliationRef="#a5"><personName><givenNames>Stephen W.</givenNames><familyName>Gutkin</familyName><degrees>BA</degrees></personName></creator><creator creatorRole="author" xml:id="cr6" affiliationRef="#a6"><personName><givenNames>Sebastian</givenNames><familyName>Sorsaburu</familyName><degrees>MD (Senior Medical Advisor, Global Drug Development)</degrees></personName></creator></creators><affiliationGroup><affiliation xml:id="a1" countryCode="US"><unparsedAffiliation>State University of New York Health Science Center at Brooklyn (SUNY Downstate Medical Center) and Kings County Hospital Center, Brooklyn, New York</unparsedAffiliation></affiliation><affiliation xml:id="a2" countryCode="CA"><unparsedAffiliation>Division of Urology, Faculty of Medicine and Dentistry, University of Western Ontario, London, Ontario, Canada</unparsedAffiliation></affiliation><affiliation xml:id="a3" countryCode="US"><unparsedAffiliation>Department of Urology, School of Nursing, University of Nursing, Charlottesville, Virginia</unparsedAffiliation></affiliation><affiliation xml:id="a4" countryCode="US"><unparsedAffiliation>Salt Lake City Veterans Affairs Medical Center & University of Utah College of Nursing, Salt Lake City, Utah</unparsedAffiliation></affiliation><affiliation xml:id="a5" countryCode="US"><unparsedAffiliation>Rete Biomedical Communications Corp., Wyckoff, New Jersey</unparsedAffiliation></affiliation><affiliation xml:id="a6" countryCode="US"><unparsedAffiliation>Eli Lilly and Company, Indianapolis, Indiana</unparsedAffiliation></affiliation></affiliationGroup><keywordGroup xml:lang="en"><keyword xml:id="k1">Assessment</keyword><keyword xml:id="k2">drug therapy</keyword><keyword xml:id="k3">erectile dysfunction</keyword><keyword xml:id="k4">phosphodiesterases</keyword><keyword xml:id="k5">risk factors</keyword><keyword xml:id="k6">sexual activity</keyword><keyword xml:id="k7">treatment outcomes</keyword><keyword xml:id="k8">vasoactive agents</keyword></keywordGroup><supportingInformation><p><b>Figure S1</b></p><p><b>Figure S2</b></p><p><b>Figure S3</b></p><p><b>Figure S4</b></p><p><b>Figure S5</b></p><p><b>Table S1</b></p><p><b>Table S2</b></p><p><b>Table S3</b></p><p><b>Table S4</b></p><supportingInfoItem><mediaResource alt="supporting info item" href="urn-x:wiley:10412972:media:jaan590:JAAN_590_sm_Supplementary"></mediaResource><caption>Supporting info item</caption></supportingInfoItem></supportingInformation><abstractGroup><abstract type="main" xml:lang="en"><title type="main">Abstract</title><p> <b>Purpose:</b> Phosphodiesterase type 5 (PDE5) inhibitors have proved to be efficacious, safe, and well tolerated, in clinical trials and practice, for men with erectile dysfunction (ED). However, many patients are not satisfied with treatment and discontinue it prematurely. This review discusses evidence‐based strategies that nurse practitioners (NPs) can use to improve diagnosis of ED, optimize patient outcomes, and identify opportunities to detect other potentially serious comorbid conditions.</p><p> <b>Data sources:</b> This article was based on a previously published review, which involved a PubMed–MEDLINE search of the clinical literature from January 1, 1998 (year of sildenafil's approval in many markets), through August 30, 2008 (date of search).</p><p> <b>Conclusions:</b> Strategies to optimize responses to PDE5 therapy are summarized by the mnemonic “<b>EPOCH</b>”: <b>E</b>valuating and <b>e</b>ducating to ensure realistic <b>e</b>xpectations of therapy; <b>P</b>rescribing a treatment individualized to the couple's needs and preferences; <b>O</b>ptimizing drug dose/regimen and revisiting key educational messages at follow‐up visits; <b>C</b>ontrolling <b>c</b>omorbidities via lifestyle counseling, medications, and/or referrals; and <b>H</b>elping patients and their partners to seek other forms of therapy if they have decided not to use a PDE5 inhibitor.</p><p> <b>Implications for practice:</b> The “EPOCH” mnemonic may remind NPs of steps to optimize treatment outcomes with PDE5 inhibitors.</p></abstract></abstractGroup></contentMeta><noteGroup><note xml:id="n-fnt-1"><p> <b>Disclosure</b>
This article was supported by Eli Lilly and Company, which had a role in data interpretation and the decision to publish the findings.</p></note></noteGroup></header></component></istex:document></istex:metadataXml><mods version="3.6"><titleInfo lang="en"><title>Optimizing treatment outcomes with phosphodiesterase type 5 inhibitors for erectile dysfunction: Opening windows to enhanced sexual function and overall health</title></titleInfo><titleInfo type="abbreviated" lang="en"><title>Optimizing ED outcomes with PDE5 inhibitors</title></titleInfo><titleInfo type="alternative" contentType="CDATA" lang="en"><title>Optimizing treatment outcomes with phosphodiesterase type 5 inhibitors for erectile dysfunction: Opening windows to enhanced sexual function and overall health</title></titleInfo><name type="personal"><namePart type="given">Richard</namePart><namePart type="family">Sadovsky</namePart><namePart type="termsOfAddress">MD, MPH, FAAFP (Associate Professor of Family Medicine)</namePart><affiliation>State University of New York Health Science Center at Brooklyn (SUNY Downstate Medical Center) and Kings County Hospital Center, Brooklyn, New York</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Gerald B.</namePart><namePart type="family">Brock</namePart><namePart type="termsOfAddress">MD, FRCSC (Professor of Urology)</namePart><affiliation>Division of Urology, Faculty of Medicine and Dentistry, University of Western Ontario, London, Ontario, Canada</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Mikel</namePart><namePart type="family">Gray</namePart><namePart type="termsOfAddress">PhD, FAANP (Professor of Acute & Specialty Care)</namePart><affiliation>Department of Urology, School of Nursing, University of Nursing, Charlottesville, Virginia</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Penny Kaye</namePart><namePart type="family">Jensen</namePart><namePart type="termsOfAddress">DNP, FNP‐C, FAANP (Assistant Professor of Acute & Chronic Care, Clinical Director of Non‐Surgical Erectile Dysfunction Clinic)</namePart><affiliation>Salt Lake City Veterans Affairs Medical Center & University of Utah College of Nursing, Salt Lake City, Utah</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Stephen W.</namePart><namePart type="family">Gutkin</namePart><namePart type="termsOfAddress">BA</namePart><affiliation>Rete Biomedical Communications Corp., Wyckoff, New Jersey</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Sebastian</namePart><namePart type="family">Sorsaburu</namePart><namePart type="termsOfAddress">MD (Senior Medical Advisor, Global Drug Development)</namePart><affiliation>Eli Lilly and Company, Indianapolis, Indiana</affiliation><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre type="review-article" displayLabel="reviewArticle"></genre><originInfo><publisher>Blackwell Publishing Inc</publisher><place><placeTerm type="text">Malden, USA</placeTerm></place><dateIssued encoding="w3cdtf">2011-06</dateIssued><edition>Received: January 2010;, accepted: April 2010</edition><copyrightDate encoding="w3cdtf">2011</copyrightDate></originInfo><language><languageTerm type="code" authority="rfc3066">en</languageTerm><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><physicalDescription><internetMediaType>text/html</internetMediaType><extent unit="figures">2</extent><extent unit="tables">4</extent><extent unit="references">90</extent></physicalDescription><abstract>Purpose: Phosphodiesterase type 5 (PDE5) inhibitors have proved to be efficacious, safe, and well tolerated, in clinical trials and practice, for men with erectile dysfunction (ED). However, many patients are not satisfied with treatment and discontinue it prematurely. This review discusses evidence‐based strategies that nurse practitioners (NPs) can use to improve diagnosis of ED, optimize patient outcomes, and identify opportunities to detect other potentially serious comorbid conditions.</abstract><abstract>Data sources: This article was based on a previously published review, which involved a PubMed–MEDLINE search of the clinical literature from January 1, 1998 (year of sildenafil's approval in many markets), through August 30, 2008 (date of search).</abstract><abstract>Conclusions: Strategies to optimize responses to PDE5 therapy are summarized by the mnemonic “EPOCH”: Evaluating and educating to ensure realistic expectations of therapy; Prescribing a treatment individualized to the couple's needs and preferences; Optimizing drug dose/regimen and revisiting key educational messages at follow‐up visits; Controlling comorbidities via lifestyle counseling, medications, and/or referrals; and Helping patients and their partners to seek other forms of therapy if they have decided not to use a PDE5 inhibitor.</abstract><abstract>Implications for practice: The “EPOCH” mnemonic may remind NPs of steps to optimize treatment outcomes with PDE5 inhibitors.</abstract><subject lang="en"><genre>keywords</genre><topic>Assessment</topic><topic>drug therapy</topic><topic>erectile dysfunction</topic><topic>phosphodiesterases</topic><topic>risk factors</topic><topic>sexual activity</topic><topic>treatment outcomes</topic><topic>vasoactive agents</topic></subject><relatedItem type="host"><titleInfo><title>Journal of the American Academy of Nurse Practitioners</title></titleInfo><genre type="journal">journal</genre><note type="content"> Figure S1 Figure S2 Figure S3 Figure S4 Figure S5 Table S1 Table S2 Table S3 Table S4 Figure S1 Figure S2 Figure S3 Figure S4 Figure S5 Table S1 Table S2 Table S3 Table S4 Figure S1 Figure S2 Figure S3 Figure S4 Figure S5 Table S1 Table S2 Table S3 Table S4 Figure S1 Figure S2 Figure S3 Figure S4 Figure S5 Table S1 Table S2 Table S3 Table S4 Figure S1 Figure S2 Figure S3 Figure S4 Figure S5 Table S1 Table S2 Table S3 Table S4 Figure S1 Figure S2 Figure S3 Figure S4 Figure S5 Table S1 Table S2 Table S3 Table S4 Figure S1 Figure S2 Figure S3 Figure S4 Figure S5 Table S1 Table S2 Table S3 Table S4 Figure S1 Figure S2 Figure S3 Figure S4 Figure S5 Table S1 Table S2 Table S3 Table S4 Figure S1 Figure S2 Figure S3 Figure S4 Figure S5 Table S1 Table S2 Table S3 Table S4Supporting Info Item: Supporting info item - </note><subject><genre>article-category</genre><topic>REVIEW</topic></subject><identifier type="ISSN">1041-2972</identifier><identifier type="eISSN">1745-7599</identifier><identifier type="DOI">10.1111/(ISSN)1745-7599</identifier><identifier type="PublisherID">JAAN</identifier><part><date>2011</date><detail type="volume"><caption>vol.</caption><number>23</number></detail><detail type="issue"><caption>no.</caption><number>6</number></detail><extent unit="pages"><start>320</start><end>330</end><total>11</total></extent></part></relatedItem><identifier type="istex">56297BF96D594B7B3EA523336A55CF21814D53FA</identifier><identifier type="DOI">10.1111/j.1745-7599.2010.00590.x</identifier><identifier type="ArticleID">JAAN590</identifier><accessCondition type="use and reproduction" contentType="copyright">©2011 The Author(s) Journal compilation ©2011 American Academy of Nurse Practitioners</accessCondition><recordInfo><recordContentSource>WILEY</recordContentSource><recordOrigin>Blackwell Publishing Inc</recordOrigin></recordInfo></mods></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Psychologie/explor/TherFamFrancoV1/Data/Istex/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001384 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Corpus/biblio.hfd -nk 001384 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Psychologie
|area= TherFamFrancoV1
|flux= Istex
|étape= Corpus
|type= RBID
|clé= ISTEX:56297BF96D594B7B3EA523336A55CF21814D53FA
|texte= Optimizing treatment outcomes with phosphodiesterase type 5 inhibitors for erectile dysfunction: Opening windows to enhanced sexual function and overall health
}}
| This area was generated with Dilib version V0.6.29. |  |